Cargando…

Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis

Herpes simplex virus (HSV) type 1 encephalitis (HSE) is a viral infectious disease with commonly occurring neurodegeneration and neurological/cognitive long-term sequelae. Kynurenic acid (KYNA) is a neuroactive tryptophan metabolite, which is elevated in the cerebrospinal fluid (CSF) during viral in...

Descripción completa

Detalles Bibliográficos
Autores principales: Atlas, Ann, Franzen-Röhl, Elisabeth, Söderlund, Johan, Jönsson, Erik G, Samuelsson, Martin, Schwieler, Lilly, Sköldenberg, Birgit, Engberg, Göran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855257/
https://www.ncbi.nlm.nih.gov/pubmed/24324341
http://dx.doi.org/10.4137/IJTR.S13256
_version_ 1782294906669105152
author Atlas, Ann
Franzen-Röhl, Elisabeth
Söderlund, Johan
Jönsson, Erik G
Samuelsson, Martin
Schwieler, Lilly
Sköldenberg, Birgit
Engberg, Göran
author_facet Atlas, Ann
Franzen-Röhl, Elisabeth
Söderlund, Johan
Jönsson, Erik G
Samuelsson, Martin
Schwieler, Lilly
Sköldenberg, Birgit
Engberg, Göran
author_sort Atlas, Ann
collection PubMed
description Herpes simplex virus (HSV) type 1 encephalitis (HSE) is a viral infectious disease with commonly occurring neurodegeneration and neurological/cognitive long-term sequelae. Kynurenic acid (KYNA) is a neuroactive tryptophan metabolite, which is elevated in the cerebrospinal fluid (CSF) during viral infection as a result of immune activation. The aim of the study was to investigate the role of endogenous brain KYNA for the long-term outcome of the disease. CSF KYNA concentration was analyzed in 25 HSE patients along the course of the disease and compared with that of 25 age-matched healthy volunteers. Within 3 weeks of admission CSF KYNA of HSE patients was markedly elevated (median 33.6 nM) compared to healthy volunteers (median 1.45 nM). Following a decline observed after 1–2 months, levels of CSF KYNA were elevated more than 1 year after admission (median 3.4 nM range: 1–9 years). A negative correlation was found between initial CSF KYNA concentrations and severity of the long-term sequelae. This study show a marked elevation in CSF KYNA from patients with HSE, most pronounced during the acute phase of the disease and slowly declining along the recovery. We propose that brain KYNA might potentially protect against neurodegeneration while causing a long-lasting loss in cognitive function associated with the disease.
format Online
Article
Text
id pubmed-3855257
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-38552572013-12-09 Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis Atlas, Ann Franzen-Röhl, Elisabeth Söderlund, Johan Jönsson, Erik G Samuelsson, Martin Schwieler, Lilly Sköldenberg, Birgit Engberg, Göran Int J Tryptophan Res Original Research Herpes simplex virus (HSV) type 1 encephalitis (HSE) is a viral infectious disease with commonly occurring neurodegeneration and neurological/cognitive long-term sequelae. Kynurenic acid (KYNA) is a neuroactive tryptophan metabolite, which is elevated in the cerebrospinal fluid (CSF) during viral infection as a result of immune activation. The aim of the study was to investigate the role of endogenous brain KYNA for the long-term outcome of the disease. CSF KYNA concentration was analyzed in 25 HSE patients along the course of the disease and compared with that of 25 age-matched healthy volunteers. Within 3 weeks of admission CSF KYNA of HSE patients was markedly elevated (median 33.6 nM) compared to healthy volunteers (median 1.45 nM). Following a decline observed after 1–2 months, levels of CSF KYNA were elevated more than 1 year after admission (median 3.4 nM range: 1–9 years). A negative correlation was found between initial CSF KYNA concentrations and severity of the long-term sequelae. This study show a marked elevation in CSF KYNA from patients with HSE, most pronounced during the acute phase of the disease and slowly declining along the recovery. We propose that brain KYNA might potentially protect against neurodegeneration while causing a long-lasting loss in cognitive function associated with the disease. Libertas Academica 2013-11-25 /pmc/articles/PMC3855257/ /pubmed/24324341 http://dx.doi.org/10.4137/IJTR.S13256 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Original Research
Atlas, Ann
Franzen-Röhl, Elisabeth
Söderlund, Johan
Jönsson, Erik G
Samuelsson, Martin
Schwieler, Lilly
Sköldenberg, Birgit
Engberg, Göran
Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title_full Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title_fullStr Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title_full_unstemmed Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title_short Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis
title_sort sustained elevation of kynurenic acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855257/
https://www.ncbi.nlm.nih.gov/pubmed/24324341
http://dx.doi.org/10.4137/IJTR.S13256
work_keys_str_mv AT atlasann sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT franzenrohlelisabeth sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT soderlundjohan sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT jonssonerikg sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT samuelssonmartin sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT schwielerlilly sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT skoldenbergbirgit sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis
AT engberggoran sustainedelevationofkynurenicacidinthecerebrospinalfluidofpatientswithherpessimplexvirustype1encephalitis